STAAR Surgical to Report Second Quarter Results on August 7, 2024

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA), a leading developer of the EVO family of Implantable Collamer® Lenses (EVO ICL™), has announced its plans to release second quarter 2024 financial results on August 7, 2024, after market close. The company will host an earnings webcast at 4:15 p.m. ET / 1:15 p.m. PT on the same day to discuss financial results and operational progress. Investors can access the webcast through the company's website or a dedicated link. STAAR Surgical has been focused on ophthalmic surgery for over 40 years and has sold more than 3,000,000 ICLs in over 75 countries. The company operates manufacturing facilities in California and Switzerland.

Positive

• STAAR Surgical has sold over 3,000,000 Implantable Collamer® Lenses (ICLs) to date
• The company markets its lenses in more than 75 countries

Negative

• None.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024, after the market close.

Event: STAAR Surgical 2Q 2024 Financial Results Webcast
Date: Wednesday, August 7, 2024
Time: 4:15 p.m. ET / 1:15 p.m. PT
Location: https://staar-surgical-2q24-earnings.open-exchange.net/

STAAR will also host an earnings webcast on Wednesday, August 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. The live webcast, including an option to pre-register, can be accessed using the preceding link or the “Investors” section of the STAAR website at https://investors.staar.com/

A replay of the webcast will be available on August 7, 2024 at approximately 8:00 p.m. Eastern at the preceding link for at least 90 days.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731225313/en/

Investors & Media

Brian Moore

Vice President, Investor Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

When will STAAR Surgical (STAA) release its Q2 2024 financial results?

STAAR Surgical (STAA) will release its second quarter 2024 financial results on Wednesday, August 7, 2024, after the market close.

What time is STAAR Surgical's (STAA) Q2 2024 earnings webcast?

STAAR Surgical's (STAA) Q2 2024 earnings webcast is scheduled for Wednesday, August 7, 2024, at 4:15 p.m. Eastern Time / 1:15 p.m. Pacific Time.

How many Implantable Collamer® Lenses (ICLs) has STAAR Surgical (STAA) sold?

STAAR Surgical (STAA) has sold more than 3,000,000 Implantable Collamer® Lenses (ICLs) to date.

In how many countries does STAAR Surgical (STAA) market its lenses?

STAAR Surgical (STAA) markets its lenses in over 75 countries.